RecruitingNCT06644274

The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Gastrointestinal Malignancies

Sponsor

Ruijin Hospital

Enrollment

40 participants

Start Date

Oct 20, 2024

Study Type

OBSERVATIONAL

Conditions

This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for gastrointestinal malignancies.

Min Age: 18 YearsMax Age: 75 Years

Pathological and clinical diagnosis of gastrointestinal malignancies requiring immunotherapy or combination immunotherapy after evaluation according to clinical guidelines.
Signed and dated informed consent form.
Commitment to comply with research procedures and co-operation in the implementation of the full research process.
The patient is in good general condition with an expected survival of > 6 months.
aged 18-75 years old.

Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc.
Intestinal perforation, complete intestinal obstruction.
Pregnant women and women who may be pregnant, women who are breastfeeding.
Non-compliant person.

Interested in this trial?

Get notified about updates and connect with the research team.

Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

NCT06644274